Radiolabelled Stripped Mucin, SM3, Monoclonal Antibody for Immunoscintigraphy of Ovarian Tumours

Granowska, M.; Mather, Stephen J.; Jobling, Thomas W.; Naeem, Mahtab A.; Burchell, Joy M.; Ylor-Papadimitriou, J Ta; Shepherd, J. H.; Britton, K. E.

doi:10.1177/172460089000500208

Cited by 28 publications

(8 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The accuracy of 99mTc-SM3 in this study, 93% (42/ 45), compared favourably with that for 11 ~In-SM3, 73% (22/30), and ~23I-SM3, 86% [21]. It also compares favourably with other published studies with other antibodies with these radiolabels [24][25][26][27][28][29].…”

Section: Discussionsupporting

confidence: 77%

See 1 more Smart Citation

Radioimmunoscintigraphy with technetium-99m-labelled monoclonal antibody, SM3, in gynaecological cancer

et al. 1993

Self Cite

View full text Add to dashboard Cite

Radioimmunoscintigraphy (RIS) with technetium-99m labelled SM3, a monoclonal antibody reacting with a polymorphic epithelial mucin glycoprotein core antigen, is evaluated. No adverse effects or thyroid uptake were observed. Studies in 45 patients (one twice) had a sensitivity for gynaecological malignancy of 100% (35/35) and a specificity of 73% (8/11), giving an overall accuracy of 93% (43/46). These results have led to the routine adoption of 99mTc RIS in the management of patients suspected of or having primary or recurrent gynaecological cancer.

show abstract

Section: Discussionsupporting

confidence: 77%

“…However, the specificity, although the numbers are small, is much improved over 1111n-SM3, which has a specificity of 33% [20,21]. This is thought to be due to a number of factors [22,23].…”

Section: Discussionmentioning

confidence: 99%

Radioimmunoscintigraphy with technetium-99m-labelled monoclonal antibody, SM3, in gynaecological cancer

et al. 1993

Self Cite

View full text Add to dashboard Cite

show abstract

“…Previous studies in ovarian cancer using 99mTc SM3 have shown less than 20% human anti-mouse antibodies and no clinical reactions (Granowska et al, 1990). They were not evaluated here.…”

Section: Discussionmentioning

confidence: 99%

99mTc-labelled SM3 in the preoperative evaluation of axillary lymph nodes and primary breast cancer with change detection statistical processing as an aid to tumour detection

Biassoni

Granowska²,

Carroll³

et al. 1998

Br J Cancer

View full text Add to dashboard Cite

“…of patients: 10-45). These findings appear to indicate that radioimmunoscintigraphy with 99mTc-MAb-170 represents a reliable diagnostic tool in cases of ovarian carcinoma [2,6,7,13,[15][16][17][18][19][20][21][22][23].…”

Section: Discussionmentioning

confidence: 98%

Radioimmunoscintigraphy of ovarian tumours with technetium-99m labelled monoclonal antibody-170: first clinical experiences

et al. 1995

View full text Add to dashboard Cite

The recently developed technetium-99m-labelled monoclonal antibody-170 (MAb-170) was designed for diagnostic use in patients suffering from gynaecological adenocarcinoma. Following in vitro studies which showed immunoreactivity of this antibody to more than 90% of human adenocarcinomas, the present investigation was initiated to verify its usefulness for radioimmunoscintigraphy of ovarian tumours. Most of the 30 patients participating in this study underwent immunoscintigraphy prior to first-look surgery. Biokinetic evaluation in two patients showed a plasma half-time of 18.9 h (mean value, n = 2, r = 0.98) and a biexponential total body curve with values of 7.7 h and 17 days (r = 0.98). The mean 24-h urinary excretion was 12% of the injected dose. Radioimmunoscintigraphy using the MAb-170 recognised 12 of 13 cases of adenocarcinoma of the ovaries, corresponding to an overall sensitivity of 92.3%. Specificity was 94.1% (16/17). The calculation of accuracy yielded a figure of 93.3% (28/30). Of 33 known lesions, 26 were visualised successfully; thus the locoregional sensitivity was 78.8%. Of 29 benign tumour sites, 28 showed no evidence of tracer accumulation, corresponding to a locoregional specificity of 96.6%. The smallest lesion visualised was an adenocarcinoma of the corpus uteri with a diameter of 1.5 cm. Technetium-99m labelled MAb-170 is a promising new radiopharmaceutical for immunoscintigraphy of ovarian adenocarcinoma.

show abstract

Radiolabelled Stripped Mucin, SM3, Monoclonal Antibody for Immunoscintigraphy of Ovarian Tumours

Cited by 28 publications

References 12 publications

Radioimmunoscintigraphy with technetium-99m-labelled monoclonal antibody, SM3, in gynaecological cancer

Radioimmunoscintigraphy with technetium-99m-labelled monoclonal antibody, SM3, in gynaecological cancer

99mTc-labelled SM3 in the preoperative evaluation of axillary lymph nodes and primary breast cancer with change detection statistical processing as an aid to tumour detection

Radioimmunoscintigraphy of ovarian tumours with technetium-99m labelled monoclonal antibody-170: first clinical experiences

Contact Info

Product

Resources

About